Survival
The median follow-up time for the surviving patients was 44.8 months (range, 3.4–74.6 months). The median OS for all the patients was 41.9 months (95% CI, 18.6–65.3 months), and the median PFS for all the patients was 38.7 months (95% CI, 23.5–53.9 months). The 3-year survival rate was 54.4% (95% CI, 40.2–69.5 %), and the 3-year PFS rate was 52.3% (95% CI, 36.3–65.7%) (Fig. Overall survival and progression-free survival. As mentioned in our previous report, the patients were divided into two groups according to whether they underwent surgery. The non-surgery group comprised two types of patients: the patients who received DCRT without surgery and those who received neither DRCT nor surgery. The median OS was significantly more favorable in the surgery group than in the non-surgery group (not reached vs 26.5 months; HR, 0.43; 95% CI, 0.19–0.97); Furthermore, in accordance with whether they underwent R0 resection, the patients were divided into the R0 group (The OS for the R0 group was significantly longer than for the non-R0 group (not reached vs 26.5 months; HR, 0.38; 95% CI, 0.17–0.85; 